Repare Therapeutics, a preclinical biotech developing gene therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company is using its CRISPR-enabled SNIPRx platform to discover and develop targeted cancer therapies forcusing on genomic instability. Repare intends to file an IND application in the 2Q20 for lead candidate,RP-3500, an oral small molecule inhibitor for the treatment of solid tumors.
Primary shareholders include Versant Ventures (30% pre-IPO stake), MPM Capital (12%), OrbiMed Advisors (11%), UBS (9%), Cowen (8%) and Fonds de solidarité FTQ (8%).
The Cambridge, MA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol RPTX. Repare Therapeutics filed confidentially on April 6, 2020. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
